丹蛭降糖胶囊对2型糖尿病合并大血管病变患者糖脂代谢及生活质量的影响 |
| |
引用本文: | 王 欢,方朝晖,赵进东,张文锦,方妍妍. 丹蛭降糖胶囊对2型糖尿病合并大血管病变患者糖脂代谢及生活质量的影响[J]. 安徽中医学院学报, 2022, 41(3): 23-27 |
| |
作者姓名: | 王 欢 方朝晖 赵进东 张文锦 方妍妍 |
| |
作者单位: | 安徽中医药大学第一附属医院,安徽 合肥 230031 |
| |
基金项目: | 国家中医药管理局中医药重点学科项目(20091221);安徽高校自然科学研究项目(KJ2020A0401);安徽中医药大学科学研究项目(2020yfyzc39) |
| |
摘 要: | 目的 观察丹蛭降糖胶囊对2型糖尿病合并大血管病变患者糖脂代谢及生活质量的影响。方法 选取2型糖尿病合并大血管病变患者50例,随机分为对照组和治疗组各25例,对照组给予西药常规治疗,治疗组加服丹蛭降糖胶囊,治疗4周,检测并对比干预前后两组患者血清空腹血糖(fasting blood glucose,FPG)、餐后2小时血糖(2-hour postprandial blood glucose,2hPG)、稳态评估模型胰岛素抵抗指数(homeostasis model assessment of insulin resistance,HOMA-IR)、三酰甘油(triacylglycerol,TG)、总胆固醇(total cholesterol,TC)、高密度脂蛋白胆固醇(high density lipoprotein cholesterol,HDL)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL)水平的变化情况;采用生存质量特异性量表(diabetes specific quality of life,DSQL)评价生存质量,根据临床症状和血糖改善情况综合判断疗效。结果 与治疗前比较,两组患者治疗后血清FPG、2hPG、TG、LDL水平均显著降低(P<0.05),HDL水平显著升高(P<0.05),且治疗组治疗后血清TC水平显著降低(P<0.05),对照组患者治疗后血清TC水平变化无统计学意义(P>0.05);与对照组比较,治疗组患者血清2hPG、TC水平下降更显著(P<0.05),HDL水平升高更显著(P<0.05);与对照组比较,治疗组患者生理功能评分降低程度显著大于对照组(P<0.05);治疗组临床疗效优于对照组(P<0.05)。结论 丹蛭降糖胶囊能显著降低2型糖尿病合并大血管病患者血清血糖血脂水平,有效拮抗患者胰岛素抵抗和血液脂毒性,提高患者生活质量和临床疗效。
|
关 键 词: | 2型糖尿病;大血管病变;丹蛭降糖胶囊;糖脂毒性 |
Effect of Danzhi Jiangtang Capsule on Glucose and Lipid Metabolism and Quality of Life in Patients with Type 2 Diabetes and Macroangiopathy |
| |
Affiliation: | The First Affiliated Hospital of Anhui University of Chinese Medicine, Anhui Hefei 230031, China |
| |
Abstract: | Objective To investigate the effect of Danzhi Jiangtang Capsule on glucose and lipid metabolism and quality of life in patients with type 2 diabetes and macroangiopathy. Methods A total of 50 patients with type 2 diabetes and macroangiopathy were randomly divided into control group and treatment group, with 25 patients in each group. The patients in the control group were given conventional Western medicine treatment, and those in the treatment group were given Danzhi Jiangtang Capsule in addition to the treatment in the control group. The two groups were compared in terms of the changes in fasting plasma glucose (FPG), 2-hour postprandial glucose (2hPG), Homeostasis Model Assessment of Insulin Resistance (HOMA-IR), triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) after intervention; Diabetes specific Quality of Life (DSQL) instrument was used to evaluate quality of life, and treatment outcome was assessed based on the improvements in clinical symptoms and blood glucose. Results After treatment, both groups had significant reductions in the serum levels of FPG, 2hPG, TG, and LDL-C (P<0.05) and a significant increase in HDL-C (P<0.05); the treatment group had a significant reduction in the serum level of TC after treatment (P<0.05), while the control group had no significant change in the serum level of TC after treatment (P>0.05). Compared with the control group, the treatment group had significantly greater reductions in the serum levels of 2hPG and TC (P<0.05) and a significantly greater increase in HDL-C (P<0.05). Compared with the control group, the treatment group had a significantly greater reduction in physiological function score (P<0.05) and a significantly better clinical outcome (P<0.05). Conclusion In patients with type 2 diabetes and macroangiopathy, Danzhi Jiangtang Capsule can significantly reduce the levels of blood glucose and blood lipids, effectively antagonize insulin resistance and blood lipotoxicity, and improve their quality of life and clinical outcome. |
| |
Keywords: | Type 2 diabetes Macroangiopathy Danzhi Jiangtang Capsule Glucolipotoxicity |
|
| 点击此处可从《安徽中医学院学报》浏览原始摘要信息 |
|
点击此处可从《安徽中医学院学报》下载全文 |
|